ReviewEcoSal Plus2018
Aminoglycoside Revival: Review of a Historically Important Class of Antimicrobials Undergoing Rejuvenation.
Review in EcoSal Plus, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 1 synthesis or guideline pooled it, 188 citations in OpenAlex.
- MT-RNR1 genotype testing for preventing aminoglycoside-mediated ototoxicity: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).British journal of clinical pharmacology · 2026Guideline
- Assembling the puzzle of antimicrobial resistance in staphylococcal biofilms.Emerging microbes & infections · 2026Article
- Population Pharmacokinetics of Amikacin in Non-Neonatal Pediatric Patients: A Scoping Review.European journal of drug metabolism and pharmacokinetics · 2026Article
- Pandemic-associated shifts in microbial ecology and antimicrobial resistance in a high-volume liver transplant intensive care unit: a 10-year surveillance study.Infection prevention in practice · 2026Article
- Repeated aminoglycoside exposure activates interferon-stimulated genes in human renal proximal tubular models.Archives of toxicology · 2026Article
- In Vitro Evaluation of Novel Nano-Sized Colloidal Assemblies Incorporating Hydrophobic Tobramycin Ion Pairs: Enhanced Cellular Uptake with Preserved Antimicrobial Activity Toward Oral Drug Delivery.Molecules (Basel, Switzerland) · 2026Article
- A Newly Identified Role of the Tectorial Membrane in Aminoglycoside Ototoxicity.bioRxiv : the preprint server for biology · 2026Article
- Identification and characteristics of a novel acquired aminoglycoside phosphotransferase, APH(3')-IVb, fromAntimicrobial agents and chemotherapy · 2026Article
- Therapeutic Strategies and Clinical Outcomes of Infections Following Anterior Cruciate Ligament Reconstruction: A Narrative Review.Orthopaedic surgery · 2026Review
- Enhancement of tobramycin and amikacin activities by co-encapsulation in liposomal-thymoquinone formulation: antibacterial, antibiofilm, and cytocompatibility study.Therapeutic delivery · 2026Article
- Pharmacologic Inhibition of JAK1/2 Potentiates Aminoglycoside-Induced Ototoxicity.Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2026Article
- Proteostasis-targeted antibacterial strategies.Journal of microbiology (Seoul, Korea) · 2026Review
- Multilayered molecular mechanisms and regulatory networks of aminoglycoside resistance in Enterobacteriaceae.Frontiers in cellular and infection microbiology · 2026Review
- Perioperative Gentamicin Prophylaxis in Robot-Assisted Prostatectomy Increases Acute Kidney Injury Risk.Urologia internationalis · 2026Article
- Coexistence and Genetic Location of Aminoglycoside-Modifying Enzyme Genes in ClinicalInfection and drug resistance · 2026Article
- Cloning and molecular characterization ofFrontiers in microbiology · 2026Article
- Frequency and antimicrobial resistance pattern of non lactose fermenting gram negative rods in neurosurgical patients outlining aminoglycoside resistance genes.BMC microbiology · 2025Article
- EPY001, a Novel Monoclonal Antibody AgainstInternational journal of molecular sciences · 2025Article
- Adaptation to cinnamaldehyde shapesJournal of bacteriology · 2025Article
- Evolution of polyamine resistance inmSphere · 2025Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aminoglycosides are cidal inhibitors of bacterial protein synthesis that have been utilized for the treatment of serious bacterial infections for almost 80 years. There have been approximately 15 members of this class approved worldwide for the treatment of a variety of infections, many serious and life threatening. While aminoglycoside use declined due to the introduction of other antibiotic classes such as cephalosporins, fluoroquinolones, and carbapenems, there has been a resurgence of interest in the class as multidrug-resistant pathogens have spread globally. Furthermore, aminoglycosides are recommended as part of combination therapy for empiric treatment of certain difficult-to-treat infections. The development of semisynthetic aminoglycosides designed to overcome common aminoglycoside resistance mechanisms, and the shift to once-daily dosing, has spurred renewed interest in the class. Plazomicin is the first new aminoglycoside to be approved by the FDA in nearly 40 years, marking the successful start of a new campaign to rejuvenate the class.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.